Julphar announces financial results for first nine months of 2012
- United Arab Emirates: Thursday, October 18 - 2012 at 14:07
- PRESS RELEASE
Julphar (Gulf Pharmaceutical Industries) registered sales revenue of Dhs902.1m in the first nine months of the year 2012, up 14.0% year-on-year (yoy). Sales during the period were driven by the tender market sales which saw a yoy growth of 28.1%.
Significant gains continued to be registered in almost all of its leading markets during the period. Libya, Iraq, Egypt, Afghanistan and Saudi Arabia saw huge gains for the company during the period under review. The top-7 markets continued to show strong growth in private and tender markets, as well as on overall basis.
Commenting on the results GVG Krishna, Julphar's Chief Financial Officer, said: "Julphar continues to see consistent growth across all of its major markets and these results remain on track with our annual forecasts. We have seen an excellent contribution from our operation in Saudi Arabia which has been Julphar's leading market for this period. Overall a strong set of results and solid performance that we anticipate will continue until the year end (December 31)."
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / 4C. AME Info FZ LLC / 4C is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.